Global Rifapentine (CAS 61379-65-5) Market Size By Type (20 Capsules/Box, 24 Capsules/Box), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Rifapentine (CAS 61379-65-5) Market was valued at USD 240 million in 2023 and is expected to reach USD 462 million by 2031, growing at a CAGR of 8.5% during the forecast period from 2023 to 2031. Rifapentine, a rifamycin derivative, plays a critical role in the treatment of tuberculosis (TB), particularly in preventive therapy for latent TB infections and drug-susceptible active TB. The increasing global burden of TB, growing adoption of shorter-course regimens, and the expansion of government-supported anti-TB programs are major contributors to the market growth.

Drivers:

1. Rising Global TB Burden and Public Health Initiatives:

The high prevalence of tuberculosis, particularly in developing regions, is a significant driver of the Rifapentine market. National TB control programs, supported by global health organizations such as WHO and the Global Fund, are encouraging the use of rifapentine-containing regimens for both latent and active TB treatment.

2. Adoption of Short-Course Treatment Regimens:

Rifapentine is a key component in the widely endorsed 3HP (3-month, once-weekly isoniazid and rifapentine) and 1HP (1-month daily isoniazid and rifapentine) regimens. These shorter, more patient-friendly treatment protocols are driving its adoption in TB-endemic countries.

3. Strategic Collaborations and Subsidized Drug Access:

Public-private partnerships and increased availability through global procurement mechanisms (like the Stop TB Partnership’s Global Drug Facility) have made rifapentine more accessible and affordable, enhancing its market penetration.

Restraints:

1. Regulatory and Pricing Barriers in Low-Income Countries:

Despite high demand, regulatory challenges and pricing issues hinder timely access in several countries. The cost of rifapentine compared to other TB drugs also limits its widespread use, particularly in lower-income healthcare settings.

2. Limited Manufacturer Base:

With few global manufacturers producing rifapentine at scale, the market faces supply-side constraints. Limited API availability and production capacity pose risks to sustained supply and price stability.

Opportunity:

1. Expanded Use in Preventive TB Therapy:

Growing interest in rifapentine-based preventive therapy for TB among HIV-positive individuals and household contacts of TB patients presents significant market potential. Its integration into HIV/AIDS and maternal-child health programs can further boost market demand.

2. Entry into New Markets via WHO Prequalification:

With increased efforts by generic drug manufacturers to obtain WHO prequalification, rifapentine is poised to enter untapped markets, especially across Africa, Southeast Asia, and Latin America.

Market by System Type Insights:

Based on product formulation, tablet-based rifapentine dominated the market in 2023, owing to its ease of use, stability, and compatibility with existing TB treatment regimens. However, the injectable segment is emerging as a promising niche, particularly in clinical settings requiring supervised administration and higher compliance.

Market by End-use Insights:

In 2023, public health institutions accounted for the largest market share due to the extensive use of rifapentine in national TB elimination programs. Meanwhile, non-governmental organizations (NGOs) and international aid programs are expected to witness the highest growth rate as global funding and outreach initiatives expand TB screening and treatment services.

Market by Regional Insights:

Asia-Pacific emerged as the leading regional market in 2023, driven by high TB incidence in countries like India, China, Indonesia, and the Philippines. North America, particularly the U.S., is also a significant market due to the FDA approval of rifapentine and its use in preventive therapy. Africa is expected to witness robust growth due to rising public health spending and international support.

Competitive Scenario:

Key players operating in the global Rifapentine market include Sanofi S.A., Macleods Pharmaceuticals, Lupin Pharmaceuticals, Otsuka Pharmaceutical, Viatris Inc., and Cadila Pharmaceuticals. Companies are focusing on partnerships with global health agencies, improving production scalability, and pursuing regulatory clearances across new geographies.

Scope of Work – Global Rifapentine (CAS 61379-65-5) Market

Key Market Developments:

2023: Sanofi announced a partnership with the Global Drug Facility to reduce the cost of rifapentine for public health programs in high-burden countries.

2024: Macleods Pharmaceuticals received WHO prequalification for its rifapentine 150 mg tablet, enabling broader global distribution.

2025: Viatris expanded its TB product line with a generic fixed-dose combination of isoniazid and rifapentine, targeting preventive therapy markets in Asia and Africa.

FAQs:

What is the current market size of the Global Rifapentine (CAS 61379-65-5) Market?

The market was valued at USD 240 million in 2023.

What is the major growth driver of the Global Rifapentine (CAS 61379-65-5) Market?

The rising TB burden and adoption of short-course regimens are the major growth drivers.

Which is the largest region during the forecast period in the Global Rifapentine (CAS 61379-65-5) Market?

Asia-Pacific holds the largest market share due to high TB incidence and public health initiatives.

Which segment accounted for the largest market share in Global Rifapentine (CAS 61379-65-5) Market?

The tablet-based formulation segment accounted for the largest share in 2023.

Who are the key market players in the Global Rifapentine (CAS 61379-65-5) Market?

Key players include Sanofi, Macleods Pharmaceuticals, Lupin Pharmaceuticals, Viatris, and Otsuka Pharmaceutical.